Evidence map›Paper›PMID 31592299›Full record

ArticlePharmacy practice

A transition from the BPharm to the PharmD degree in five selected countries.

Teeraporn Supapaan, Bee Y Low, Payom Wongpoowarak, Summana Moolasarn, Claire Anderson

Abstract read
In one paragraph

Article in Pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. [German pharmacy degree course: an international comparison].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Teeraporn SupapaanFaculty of Pharmaceutical Sciences, Ubon Ratchathani University. Ubon Ratchathani (Thailand). teeraporn.s@ubu.ac.th.ORCID 0000-0002-6887-8181
Bee Y LowSchool of Pharmacy, Faculty of Science and Engineering, University of Nottingham Malaysia. Selangor, (Malaysia). BeeYean.Low@nottingham.edu.my.ORCID 0000-0002-1841-0169
Payom WongpoowarakDepartment of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University. Songkhla (Thailand). wpayom@gmail.com.ORCID 0000-0001-7262-147X
Summana MoolasarnFaculty of Pharmaceutical Sciences, Ubon Ratchathani University. Ubon Ratchathani (Thailand). summana@hotmail.com.
Claire AndersonSchool of Pharmacy, University of Nottingham. Nottingham (United Kingdom). Claire.Anderson@nottingham.ac.uk.ORCID 0000-0002-5406-2296

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review focuses on the studies and opinions around issues of transition from the BPharm to the PharmD degree in the U.S., Japan, South Korea, Pakistan and Thailand. The transition to the clinically orientated PharmD degree in many countries was seen to be a means of developing the profession. However, some countries have both clinically-oriented and pharmaceutical sciences-oriented PharmD programme that are designed to meet the needs of their countries. Each country created a different process to handle the transition to an all-PharmD programme, but mostly had the process of school accreditation mandated by the regulatory bodies. The main barrier to the transition in most of the countries was the issue of educational quality. A set of indicators is needed to measure and monitor the impact/outcome of the PharmD degree. Each country has different needs due to the different contexts of health care systems and the scope of pharmacy practice. In order to increase their chances of benefiting from the new programme, academic leaders should critically assess their countries' needs before deciding to adopt a PharmD programme.

Indexed as

Clinical CompetenceCurriculumEducationJapanPakistanPharmaceutical ServicesPharmacyProgram DevelopmentRepublic of KoreaSchoolsStudentsThailandUnited States

Identifiers

PMID31592299
PMCPMC6763299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.